NC
RYTM icon

nVerses Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

nVerses Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+1,908
New +$173K 0.33% 178

Other funds holding RYTM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

nVerses Capital's RYTM Position: Q2 2026 in Review

nVerses Capital opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 1,908 shares worth $212K. The stake represents 0.33% of the portfolio and ranks #178 among its holdings.

203 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • nVerses Capital held 1,908 shares of Rhythm Pharmaceuticals worth $212K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new nVerses Capital position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.33% of nVerses Capital's portfolio in Q2 2026, its #178 holding.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.